Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential

Thomas Antoine¹, Nicholas Fisher¹, Richard Amewu², Paul M. O'Neill², Stephen A. Ward¹ and Giancarlo A. Biagini^{1*}

¹Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK; ²Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK

*Corresponding author. Tel: +44-151-7053151; Fax: +44-151-7053371; E-mail: biagini@liverpool.ac.uk

Received 5 June 2013; returned 28 August 2013; revised 27 September 2013; accepted 15 November 2013

Objectives: Artemisinin and artemisinin semi-synthetic derivatives (collectively known as endoperoxides) are firstline antimalarials for the treatment of uncomplicated and severe malaria. Endoperoxides display very fast killing rates and are generally recalcitrant to parasite resistance development. These key pharmacodynamic features are a result of a complex mechanism of action, the details of which lack consensus. Here, we report on the primary physiological events leading to parasite death.

Methods: Parasite mitochondrial ($\Delta \Psi_m$) and plasma membrane ($\Delta \Psi_p$) electrochemical potentials were measured using real-time single-cell imaging following exposure to pharmacologically relevant concentrations of endoperoxides (artemisinin, dihydroartemisinin, artesunate and the synthetic tetraoxane RKA182). In addition, mitochondrial electron transport chain components NADH:quinone oxidoreductase (alternative complex I), bc_1 (complex III) and cytochrome oxidase (complex IV) were investigated to determine their functional sensitivity to the various endoperoxides.

Results: Parasite exposure to endoperoxides resulted in rapid depolarization of parasite $\Delta \Psi_m$ and $\Delta \Psi_p$. The rate of depolarization was decreased in the presence of a reactive oxygen species (ROS) scavenger and Fe³⁺ chelators. Depolarization of $\Delta \Psi_m$ by endoperoxides is not believed to be through the inhibition of mitochondrial electron transport chain components, owing to the lack of significant inhibition when assayed directly.

Conclusions: The depolarization of $\Delta \Psi_m$ and $\Delta \Psi_p$ is shown to be mediated via the generation of ROS that are initiated by iron bioactivation of endoperoxides and/or catalysed by iron-dependent oxidative stress. These data are discussed in the context of current hypotheses concerning the mode of action of endoperoxides.

Keywords: Plasmodium, mitochondria, iron, haem, lipid peroxidation, free radicals, oxidative damage

Introduction

Artemisinin is a tetracyclic 1,2,4-trioxane containing an endoperoxide bridge (C-O-O-C; Figure 1), the key pharmacophore of the drug.¹ To improve the solubility and pharmacological activity of artemisinin, a first series of semi-synthetic compounds were synthesized with a similar backbone but with modifications at the C₁₀ position, generating hemi-acetal, ether or ester derivatives such as dihydroartemisinin, artemether and artesunate (Figure 1). Artemisinins possess potent antimalarial activity and the WHO recommends the use of artemisinin combination therapy for first-line therapy of *Plasmodium falciparum* malaria worldwide. Based on the structure of the endoperoxide bridge, extensive studies have been devoted to the synthesis of fully synthetic endoperoxides, some of which are currently in clinical and pre-clinical development (e.g. OZ439, an ozonide designed to provide a single-dose oral antimalarial cure in humans, and the tetraoxane RKA182; Figure 1).^{2,3}

The mechanism(s) of activation and subsequent biological target(s) of endoperoxides continue to be debated.⁴ The antimalarial activity of the artemisinins and related bioactive endoperoxides is believed to be mediated by activation of the endoperoxide bridge. Located in the core of the structure, its cleavage generates short-lived cytotoxic oxyradicals in the presence of haem iron or free iron Fe^{2+, 5,6} From this premise of 'endoperoxide bioactivation', two different mechanisms have been proposed. The first, proposed by the Posner laboratory using ¹⁸O-labelled trioxane analogues, hypothesizes that the oxygen-centred radicals.^{7,8} In this 'reductive

© The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

	(d)		
	Drug	R	In vitro IC ₅₀ (nM)
	Artemisinin	0	7.5 <u>+</u> 0.2
H O H H O H	Dihydroartemisinin	ОН	3.48 <u>+</u> 0.60
\mathbf{A}	Artesunate	OCO(CH ₂) ₂ CO ₂ NA	1.60 <u>+</u> 0.40
(c) (c)	Artemether	OCH ₃	4.46 <u>+</u> 0.75
	Deoxyartemisinin		>10 000
	Tetraoxane (RKA182)	N_NN-	1.30 <u>+</u> 0.61

Figure 1. Chemical structures of endoperoxides, their corresponding *P. falciparum* growth inhibition values. Chemical structures of (a) artemisinin and its semi-synthetic derivatives, (b) deoxyartemisinin and (c) the synthetic 1,2,4,5-tetraoxane drug-development candidate RKA182 used in this study. The endoperoxide bridge is highlighted in grey. (d) *P. falciparum* growth inhibition IC_{50} values of endoperoxide antimalarials. Values are the mean \pm SEM of results from three independent experiments.

scission' model, ferrous iron binds to either O1 or O2 cleaving the endoperoxide bond and generating oxyradical intermediates (Figure S1, available as Supplementary data at JAC Online). Both radicals subsequently rearrange to primary or secondary carboncentred radicals via either β -scission or a [1,5]-H shift. In support of this hypothesis, evidence of the formation of these carboncentred radical intermediates has been provided using electron paramagnetic resonance spin-trapping techniques.^{9–11} It has been proposed that these C-centred radicals are capable of haem and/or protein alkylation; whilst Meunier and coworkers¹² have provided evidence for haem alkylation, there are only a few reports of model studies on protein alkylation involving reactions with ferrous salts in the presence of cysteine (iron–sulphur chelates).¹³

In the second model, it is hypothesized that iron acts as a Lewis acid to facilitate ionic activation of antimalarial trioxanes generating downstream reactive oxygen species (ROS; Figure S1, available as Supplementary data at *JAC* Online).^{14,15} The ring opening involves heterolytic cleavage of the endoperoxide bridge followed by interaction with water generating an open, unsaturated hydroperoxide, capable of direct oxidation of protein residues. Fenton degradation of the oxygen-centred radical intermediate can provide hydroxyl radicals (HO) highly reactive against amino acids, lipids or nucleic acids.

An alternative pathway of artemisinin bioactivation has been suggested via electron transport chain (ETC) components causing downstream ROS production and membrane depolarization in isolated *Plasmodium* mitochondria.^{16,17} Analogous to this hypothesis, a further hypothesis known as the 'cofactor model' proposes that endoperoxides are reduced by redox-active flavoenzymes, resulting in the perturbation of redox homeostasis coupled with the generation of ROS (Figure S1, available as Supplementary data at *JAC* Online).¹⁸ The cofactor model of artemisinin activation, however, is not restricted to mitochondrial flavoenzymes but rather implicates cytosolic flavoenzymes and also rejects the direct requirement for either Fe²⁺ and/or non-haem iron activation.

For models involving iron-based activation, the origin of the iron available for bioactivation is also a point of debate. There is experimental evidence for the involvement of both haem and non-haem iron in the bioactivation. $^{19,20}\,$

The involvement of haem in the activation of endoperoxide compounds was first proposed following isolation of haem-artemisinin adduct in *P. falciparum* cultures.⁶ By using [¹⁴C]artemisinin, Maeno et al.²¹ showed its accumulation in the digestive food vacuole where haemoglobin degradation leads to the release of soluble haem. More recently, inhibition of haemoglobin digestion by the genetic deletion of cysteine protease falcipain-2 was shown to significantly attenuate in vitro endoperoxide-mediated parasite kill.²² Haem has been observed to enhance the oxidizing effects of endoperoxide drugs.²³ As noted above, the reaction between haem and artemisinin has been confirmed in vitro and in vivo. 12,24,25 In addition, it has been proposed that haem is the primary activator of artemisinin, reacting with it more efficiently than other iron-containing molecules (Fe²⁺, haemin or haemoglobin).²⁶ It has also been reported that antimalarial trioxanes accumulated into the food vacuole are activated by neutral lipid-associated haem and induce oxidative membrane damage.^{27,28}

However, using radio- or fluorescent-labelled artemisinins and microscopy, two studies contest the accumulation of endoperoxide drugs in the food vacuole and their possible interaction with haem.^{29,30} Additionally, Haynes *et al.*^{31,32} have proposed that artemisinins do not inhibit haemozoin formation and cannot react with haem according to conventional chemistry models. Several studies have shown that iron chelation, selective for non-haem iron, antagonizes the accumulation and antimalarial activity of endoperoxide antimalarials *in vitro* and can prevent their toxic effects in mice.^{5,30,33}

Once activated, endoperoxide antimalarials have been reported to disrupt a number of parasite functions and enzymes, including the haem detoxification pathway,²³ the translationally controlled tumour protein (*Pf*TCTP),³⁴ the sarco/endoplasmic reticulum membrane calcium *Pf*ATPase6³⁰ and the parasite mitochondrion. Specific targeting of parasite mitochondria by endoperoxides was reported initially based on morphological changes to mitochondria following exposure to artemether.^{20,35,36} Zhao *et al.*³⁷ reported a specific inhibitory effect by artemether against *Plasmodium* cytochrome *c* oxidase (complex IV) that was later also reported by Krungkrai *et al.*³⁸ based on measurements of O₂ consumption. Li *et al.*¹⁶ hypothesized a role for parasite mitochondria, specifically the type II NADH:quinone oxidoreductase (*Pf*NDH2),^{39,40} by acting both as a target and as an activator of endoperoxides via electron donation by the ETC. Conflicting data have since emerged, with Crespo *et al.*⁴¹ only observing mitochondrial dysfunction (as determined by rhodamine 123 fluorescence) upon exposure to artemisinin after 8 h but not after 4 h, interpreting this as a downstream effect rather than an initiator of killing. Conversely, Wang *et al.*¹⁷ reported depolarization of the membrane potential of isolated parasite mitochondria by artemisinin following 2 h of incubation.

Studies of artemisinin toxicity in human cells indicate that respiring mitochondria play an essential role in endoperoxide-induced cytotoxicity via the generation of ROS; however, using HeLa ρ^0 cells, which are devoid of a functioning ETC, it was demonstrated that the ETC does not have any role in the reductive activation of the endoperoxide to cytotoxic carbon-centred radicals.⁴²

We have previously described the use of a real-time single-cell imaging method for monitoring malaria parasite mitochondrial $(\Delta\Psi_m)$ and plasma membrane potential $(\Delta\Psi_p)^{43,44}$ and reported malaria parasite ETC activities including *Pf*NDH2.^{40,45} Using these approaches, we have re-examined the effect of endoperoxides on parasite bioenergetic functions and discuss our data in the context of the current hypotheses.

Materials and methods

Parasites, culture and drug sensitivity testing

P. falciparum (3D7 strain) cultures consisted of a 2% (v/v) suspension of O+ erythrocytes in RPMI 1640 medium (R8758, glutamine and NaHCO₃) supplemented with 10% pooled human AB+ serum, 25 mM HEPES (pH 7.4) and 20 μ M gentamicin sulphate.⁴⁶ Cultures were grown under a gaseous headspace of (in v/v) 4% O₂ and 3% CO₂ in N₂ at 37°C. Parasite growth was synchronized by treatment with sorbitol.⁴⁷ Drug susceptibilities were determined with an inoculum size of 0.5% parasitaemia (ring stage) and 1% haematocrit and were assessed by the measurement of fluorescence after the addition of SYBR Green I as described previously.⁴⁸ Drug 50% inhibitory concentration (IC₅₀) values were calculated from the log of the doseresponse relationship, as fitted with Grafit software (Erithacus Software, Horley, UK). Drug stock solutions (1–10 mM) were prepared in DMSO. The results are given as the means of at least three separate experiments.

Preparation of P. falciparum cell-free extracts

Free parasites were prepared from aliquots of infected erythrocytes ($\sim 8 \times 10^9$ cells/mL) by adding 5 volumes of 0.15% (w/v) saponin in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 1.76 mM K₂HPO₄, 8.0 mM Na₂HPO₄ and 5.5 mM D-glucose, pH 7.4) for 5 min, followed by three washes by centrifugation and resuspension in HEPES (25 mM)-buffered RPMI containing a protease inhibitor cocktail (Complete Mini; Roche, Mannheim, Germany). Cell extract was prepared by repeated freeze-thawing in liquid N₂, followed by disruption with a sonicating probe.

Preparation of decylubiquinol

The artificial quinol electron donor was prepared based on a previously described method.⁴⁹ Briefly, 2,3-dimethoxy-5-methyl-*n*-decyl-1,4-benzoquinone (decylubiquinone), an analogue of ubiquinone (Sigma, St Louis, MO, USA), was dissolved (10 mg) in 400 μ L of nitrogen-saturated hexane. An equal volume of aqueous 1.15 M sodium dithionite was added and the mixture shaken vigorously until colourless. The upper, organic phase was collected and the decylubiquinol recovered by evaporating off the hexane under N₂. The decylubiquinol was dissolved in 100 μ L of 96% ethanol (acidified with 10 mM HCl) and stored in aliquots at -80° C. Decylubiquinol concentration was determined spectrophotometrically from absolute spectra, using $\epsilon_{288-320}=4.14$ mM⁻¹ cm⁻¹.

Measurement of bc1 protein and complex IV activities

Decylubiquinol:cytochrome c oxidoreductase (bc1 protein) and cytochrome c oxidase (complex IV) activity were assayed in a Cary 4000 spectrophotometer (Varian Inc., USA). The bc1 reaction buffer consisted of 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN (1 M stock solution, pH adjusted to 7.5) and 30 μ M horse heart cytochrome c (oxidized) (Sigma).⁴ The complex IV mixture is composed of 50 mM potassium phosphate (pH 7.5), 2 mM EDTA and 5 μ M antimycin. Inhibitors were added prior to the addition of substrate. The reaction volume was 700 µL and assays were performed at room temperature. P. falciparum bc_1 and complex IV were assayed from cell-free P. falciparum extract at a total protein concentration of $30-60 \mu g/mL$. Cytochrome *c* reductase (*bc*₁) and oxidase (complex IV) activities were initiated, respectively, by the addition of 50 μ M decylubiquinol (dQH₂) and 30 μ M equine cytochrome c (reduced). The horse heart cytochrome *c* was reduced by sodium dithionite and then passed through a PD-10 desalting column (Pharmacia, Piscataway, NJ, USA). Activities were measured by monitoring the cytochrome c (reduced) concentration at 550-542 nm ($\varepsilon_{550-542}$ =18.1 mM⁻¹ cm⁻¹).

Measurement of PfNDH2 activity

*P*fNDH2 enzyme activity was determined based on a modification of the NADH:quinone oxidoreductase assay previously described.⁵⁰ Enzyme activity was measured in a buffered solution (final volume 0.7 mL) containing 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN and 50 μM coenzyme Q₁ at room temperature. Recombinant *P*fNDH2 enzyme was added as an *Escherichia coli* crude membrane preparation at a total protein concentration of between 10 and 20 μg/mL.⁴⁰ Inhibitors were added before initiation of the reaction by addition of 200 μM NADH. *P*fNDH2 activity was measured spectrophotometrically by monitoring the decrease of NADH concentration at 340 nm ($ε_{340}$ =6.22 mM⁻¹ cm⁻¹) and Q₁ concentration at 283 nm ($ε_{283}$ =8.1 mM⁻¹ cm⁻¹).

Real-time single-cell monitoring of membrane potential

The rhodamine derivative tetramethyl rhodamine ethyl ester (TMRE) was used to monitor the membrane potential of the cytoplasm and mitochondria from malaria-infected red blood cells. TMRE is cationic and reversibly


Table 1. Inhibitory profiles of endoperoxide compounds for three majorcomponents of the ETC of *P. falciparum* (3D7 strain)

		Percentage inhibition			
Inhibitor	PfNDH2	<i>bc</i> ¹ (complex III)	complex IV		
Artemisinin (1 μM)	17.1±4.2	3.2±3.7	18.4±4.3		
Tetraoxane (1 µM)	12.3 <u>+</u> 4.9	23.2 <u>+</u> 4.2	19.1 ± 2.0		
Dihydroartemisinin (1 µM)	5.0±4.3	6.7 ± 4.1	21.1 ± 7.9		
Artesunate (1 µM)	3.7±2.9	2.3 ± 0.4	21.1 ± 3.9		
Artemether (1 μ M)	4.1 ± 3.3	1.8 ± 1.9	23.0 ± 2.0		
HDQ (100 nM)	88.1 ± 0.5	ND	ND		
Atovaquone (50 nM)	ND	89.0 ± 1.0	ND		
Cyanide (15 mM)	ND	ND	100 ± 0.0		

Specific inhibitors of PfNDH2 [1-hydroxy-2-dodecyl-4(1H)quinolone; HDQ], bc_1 protein (atovaquone) and complex IV (cyanide) were used as positive controls. Direct activity assays were performed on recombinant PfNDH2 enzymes, whereas bc_1 protein and complex IV were assayed with cell-free parasite extracts.

Inhibitor concentrations used are indicated in brackets.

Values are means \pm SEM; n = 3 independent experiments. ND, not determined.



accumulates inside energized membranes according to the Nernst equation. For the experiment, suspensions (1%) of infected erythrocytes in HEPESbuffered RPMI medium (no serum) were loaded with 250 nM TMRE (Molecular Probes, Eugene, OR, USA) for 10 min at 37°C. For imaging, malaria parasite-infected erythrocytes were immobilized using polylysine-coated coverslips in a Bioptechs FCS2 perfusion chamber (Bioptechs, Butler, PA, USA) and maintained at 37°C in growth medium (no serum). Inhibitors were added to the perfusate and the membrane potential-dependent fluorescence responses were monitored in real time. During all manipulations, the concentration of TMRE in the perfusate was kept at 250 nM. The fluorescence signals from malaria-infected erythrocytes were collected on a Zeiss Pascal confocal laser scanning microscope through a Plan-Apochromat 63×1.2 numerical aperture water objective. Excitation of TMRE was performed using the HeNe laser line (543 nm). Emitted light was collected through a 560 nm long-pass filter from a 543 nm dichroic mirror. Photobleaching (the irreversible damage of TMRE producing a less fluorescent species) was assessed by continuous exposure (5 min) of loaded cells to laser illumination. For each experiment, the laser illumination and microscope settings that gave minimal reduction in signal were used. Data capture and extraction were carried out with Zeiss Pascal software and plot design was performed with Kaleidagraph (Synergy Software, Reading, PA, USA).

Results

Endoperoxides have a minimal inhibitory effect on the major mitochondrial respiratory chain components

As described, there is conflicting evidence on the role of the parasite ETC in the activation and/or resultant mitochondrial dysfunction following the exposure of parasites to endoperoxides. To determine whether there is a direct inhibitory effect of endoperoxides on ETC components, activities from three of the main ETC enzymes, PfNDH2, bc1 complex and cytochrome c oxidase, were measured directly in the presence of a number of endoperoxides. As described in the Materials and methods section, the bc_1 complex (complex III) and cytochrome c oxidase (complex IV) were measured directly from parasite cell-free extracts, whilst PfNDH2 activity was measured from membrane preparations of a heterologous expression system described previously. 40 No or relatively weak ($\sim\!20\%$) inhibition of the individual respiratory components was observed for all the endoperoxides tested at comparatively high fixed doses (1 µM final concentration; Table 1). Positive controls using selective inhibitors of the individual respiratory components were consistent with previously reported inhibitory values (Table 1).

Endoperoxides collapse membrane potential-dependent accumulation of TMRE in P. falciparum-infected erythrocytes

To determine the effect of endoperoxides on membrane potential, a real-time single-cell imaging approach was used. The measurement is based on the accumulation of the cationic fluorescence probe TMRE according to the Nernst equation. Due to dynamic fluorescence measurements, the probe is subject to photobleaching. To minimize this, several parameters of the confocal laser scanning microscope (laser power, scan speed, pinhole diameter, number of scan sweeps and degree of magnification) were optimized before recording each experiment. Upon addition of TMRE to *P. falciparum*-infected erythrocytes, a strong fluorescence signal was observed from the whole cytosol (except the food vacuole), corresponding to the addition of plasma and mitochondrial membrane potential. For all assays, the fluorescence dynamic range was set up so that untreated TMRE-loaded cells were regarded as having complete fluorescence (100%), whereas the baseline (0%) was set by the addition of 10 μ M H⁺ ionophore carbonyl cyanide *p*-(trifluoromethyl)phenylhydrazone (FCCP).

The endoperoxide compounds used in this study were shown to inhibit parasite growth in the low nanomolar range, consistent with previous studies (Figure 1). Addition of endoperoxides to trophozoite-stage parasites (100 nM) resulted in a 55%–60% reduction of total membrane potential-dependent fluorescence within <3 min (Figure 2c–f). Using the same conditions, atovaquone, the selective bc_1 complex inhibitor, decreased the total membrane potential-dependent fluorescence.⁴³ In contrast, addition of deoxyartemisinin, which lacks the endoperoxide bridge (Figure 1), resulted in the minimal loss of membrane potential-dependent fluorescence, consistent with its poor antimal-arial activity (Figure 2b).

Although these experiments demonstrate for the first time the rapid depolarization of membrane potential upon exposure to endoperoxides, since there is a contribution from both plasma $(\Delta\Psi_p)$ and mitochondrial membrane $(\Delta\Psi_m)$ potentials to TMRE accumulation, further experiments were performed to measure $\Delta\Psi_p$ and $\Delta\Psi_m$ independently.

Depolarization of the mitochondrial membrane potential by endoperoxides

To evaluate the impact of endoperoxides on $\Delta\Psi_m$, cells were pretreated with concanamycin A, a V-type H⁺-ATPase inhibitor. Upon addition of concanamycin A (200 nM), the fluorescence intensity from the cytosol decreases \sim 70%–80%,⁴³ leaving a local and strong signal originating from the parasite mitochondrion, as demonstrated in Figure 3(b). To measure $\Delta\Psi_m$ -dependent fluorescence, concanamycin A-treated parasites were normalized to 100% and the baseline (0%) was set by FCCP addition (10 μ M). Atovaquone addition rapidly (\approx 3 min) reduced concanamycin-independent TMRE fluorescence by 70% (Figures 3 and 4a). Similarly, both artemisinin and tetraoxane decreased the concanamycin-independent TMRE fluorescence by 60% and 50%, respectively (Figures 3 and 4b and c).

Depolarization of the plasma membrane potential by endoperoxides

The $\Delta\Psi_m$ was demonstrated to represent between 20% and 30% of the total cellular TMRE fluorescence, leaving a homogeneous cytosolic signal originating from the plasma membrane only.⁴³ To evaluate the $\Delta\Psi_p$ -dependent fluorescence, parasites were pretreated with 100 nM atovaquone for 5 min before addition of the endoper-oxide inhibitor. For these experiments, atovaquone-treated parasites were normalized to 100% and the baseline (0%) was set by

Figure 2. Effect of endoperoxide antimalarials on both the plasma and mitochondrial membrane potential of *P. falciparum*. Time course of TMRE-dependent fluorescence of *P. falciparum*-infected erythrocytes after the addition of (a) 100 nM atovaquone, (b) 100 nM deoxyartemisinin, (c) 100 nM artemisinin, (d) 100 nM tetraoxane (compound RKA182), (e) 100 nM artesunate and (f) 100 nM dihydroartemisinin. The data were normalized to 100% in untreated cells and to 0% in FCCP (10 μ M)-treated cells. Graphs show means from experiments performed independently \pm standard errors ($n \ge 7$).




Figure 3. Effect of atovaquone, artemisinin and tetraoxane (RKA182) on fluorescent mitochondria from *P. falciparum* trophozoites. Bright-field fluorescence (a) and TMRE fluorescence images of concanamycin-pretreated infected erythrocytes before induction (b) and 300 s after induction (c) with 100 nM atovaquone (1), 100 nM artemisinin (2) and 100 nM tetraoxane (3). The green in these images is a pseudocolour. 'M' indicates the parasite mitochondrion and 'FV' indicates the food vacuole.

FCCP addition (10 μ M). The vacuolar H⁺-ATPase is involved in transforming the energy of ATP hydrolysis to generate the electrochemical potential at the surface of the malaria parasite through the transport of H⁺ across the plasma membrane.⁵¹ As expected, the addition of concanamycin A, a well-known V-type ATPase inhibitor, rapidly decreased $\Delta\Psi_p$ -dependent fluorescence by 60% (Figure 5a). In a similar manner, artemisinin and tetraoxane were observed to decrease the atovaquone-independent fluorescence signal by 40% and 60%, respectively (Figure 5b and c).

The described data confirm that both $\Delta \Psi_m$ and $\Delta \Psi_p$ are rapidly depolarized upon exposure to physiological concentrations of endoperoxides. The next set of experiments was performed to ascertain whether the rapid depolarization would be affected by chelation of free Fe³⁺, as previously hypothesized by other studies.

Effect of Fe³⁺ chelators desferrioxamine (DFO) and deferipone (DFP) on the membrane potential depolarization by artemisinin and tetraoxane

DFO and DFP, two chelating agents selective for non-haem Fe³⁺,⁵² were used at a fixed dose to determine the effect of free iron on the rapid endoperoxide-induced, parasite total ($\Delta \Psi_m$ and $\Delta \Psi_p$) membrane potential depolarization.

Growth inhibition studies (48 h IC₅₀) using both iron chelators revealed moderate antimalarial activity against 3D7 *P. falciparum*

of $17.3 \pm 2 \mu$ M (DFO) and $111.8 \pm 2 \mu$ M (DFP). However, during the short time period of the single-cell assays (<6 min), the addition of 100 μ M DFO or 100 μ M DFP to the perfusate did not result in a decrease of parasite $\Delta \Psi_m$ and $\Delta \Psi_p$ -dependent fluorescence signal. However, addition of DFO and DFP (100 μ M) to the perfusate was observed to significantly minimize the depolarization caused by either artemisinin (100 nM; Figure 6a) or tetraoxane (100 nM; Figure 6b), relative to chelator-free controls. For both endoperoxides, DFO was observed to confer areater protection than DFP.

Next, it was investigated whether ROS scavengers would also confer a protective effect against endoperoxides as postulated in previous studies.

Effect of the superoxide scavenger Tiron on the membrane potential depolarization induced by artemisinin and tetraoxane

Tiron, a cell membrane-permeable superoxide scavenger, was added (100 μ M) to the perfusate and endoperoxide-induced $\Delta\Psi_m$ and $\Delta\Psi_p$ depolarization was measured as described previously. Tiron was clearly observed to have a significant protective effect against endoperoxide-induced membrane potential depolarization, decreasing the rate of depolarization by >50% for both artemisinin and tetraoxane (Figure 7). In control experiments, Tiron alone had no




Figure 4. Effect of artemisinin and tetraoxane on mitochondrial membrane potential only. Plasma membrane potential is depolarized by treatment of *P. falciparum*-infected erythrocytes with 200 nM concanamycin A before addition of inhibitors. Time course of TMRE-plasma independent fluorescence is followed after addition of (a) 10 nM atovaquone, (b) 100 nM artemisinin and (c) 100 nM tetraoxane. Data were normalized to 100% in untreated cells and to 0% in FCCP (10 μ M)-treated cells. Graphs show means from experiments performed independently \pm standard errors ($n \ge 7$).

effect on parasite $\Delta \Psi_{\rm m}$ and $\Delta \Psi_{\rm p}$ based on TMRE fluorescence (data not shown).

Discussion

ETC components are not a direct target for endoperoxides

Specific inhibition by endoperoxides has previously been reported for *Plasmodium* cytochrome *c* oxidase (complex IV)^{37,38} and type II NADH:quinone oxidoreductase (*Pf*NDH2).¹⁶ In agreement with previous studies, we also noted inhibition of complex IV but only to a maximum of 20% at relatively high concentrations (1 μ M) of a range of endoperoxides (Table 1). Little or no inhibition was observed, however, for either recombinant *Pf*NDH2 or *bc*₁ (Table 1). It should be noted that all enzymatic assays were performed using either cell-free extracts or *E. coli* membrane preparations and would be expected to have contained trace Fe²⁺ and, for the parasite extract, haem. These data indicate that ETC components are not direct targets for endoperoxide inhibition in *Plasmodium*. Previous studies reporting inhibition of *Pf*NDH2 by endoperoxides¹⁶ did not measure the enzyme directly, but rather showed increased sensitivity to endoperoxides in yeast transfected with *Pf*NDH2. It is likely, therefore, that *Pf*NDH2 in the yeast system increased sensitivity to endoperoxides via an indirect effect, possibly by serving as a source of ROS by electron transfer from the *Pf*NDH2 flavin to O₂ or potentially directly to the endoperoxides.

Rapid loss of parasite vitality upon exposure to endoperoxides

In unicellular organisms, life can be defined as the maintenance of an electrochemical potential across the organism's outer




Figure 5. Effect of artemisinin and tetraoxane on plasma membrane potential only. Mitochondrial membrane potential is depolarized by treatment of *P. falciparum*-infected erythrocytes with 100 nM atovaquone before addition of inhibitors. Time course of TMRE-mitochondrial independent fluorescence is followed after addition of (a) 200 nM concanamycin A, (b) 100 nM artemisinin and (c) 100 nM tetraoxane. Data were normalized to 100% in untreated cells and to 0% in FCCP (10 μ M)-treated cells. Graphs show means from experiments performed independently \pm standard errors ($n \ge 7$).

membrane (negative entropy).⁵³ Plasmodia have a proton potential across the plasma membrane ($\Delta\Psi_{\rm p}$) of ~ -95 mV.^{51,54} It is generated by V-type H⁺-ATPases, which transfer protons out of the parasite cytosol.^{55,56} Localized in the plasma membrane, the V-type H⁺-ATPase also plays a role in regulating a neutral cytosolic pH (near 7.3), crucial for enzyme function, incorporation of vitamin B5 and generation of a pH gradient across membranes of internal organelles.^{56,57} The maintenance of a $\Delta\Psi_{\rm p}$ is also important in mediating the influx of K⁺ in the parasite cytosol and the uptake of nutrients such as choline.^{51,58,59} The direct inhibition of the V-type H⁺-ATPase by specific inhibitors such as bafilomycin A₁ or concanamycin A has been demonstrated to depolarize the plasma membrane potential and disrupt the physiology of the parasite, leading to its death.^{43,51,57} The parasite mitochondrial membrane potential ($\Delta\Psi_{\rm m}$) is generated via the ETC, through the activity of the bc_1 complex and cytochrome c oxidase.^{43,60}

An essential function of the mitochondrion for parasite survival during the intraerythrocytic stages is the provision of orotate for pyrimidine biosynthesis through the activity of dihydroorotate dehydrogenase. 61,62

Exposure of *P. falciparum*-infected erythrocytes to pharmacologically relevant concentrations of endoperoxides resulted in a rapid loss of membrane potential-dependent accumulation of TMRE (Figure 2). On account of the comparatively high contribution by the $\Delta \Psi_p$ (relative to mammalian cells), it was not possible from these experiments to distinguish whether the depolarization was on account of an effect on the $\Delta \Psi_p$ alone and/or the $\Delta \Psi_m$. Inhibition of the parasite V-type H⁺-ATPase by addition of concanamycin A to the perfusate 'unmasked' the parasite to reveal the $\Delta \Psi_m$ dependent accumulation of TMRE (Figure 3). With this manipulation, it was possible to determine that for all the endoperoxide classes tested, $\Delta \Psi_m$ was rapidly depolarized (Figure 4). These




Figure 6. Effect of artemisinin and tetraoxane on the membrane potential in the presence of iron chelators. Time course of TMRE-dependent fluorescence of *P. falciparum*-infected erythrocytes after addition of (a) 100 nM artemisinin and (b) 100 nM tetraoxane. Cells are not treated (open circles) or subjected to iron chelator treatment with 100 μ M DFO (filled circles) or 100 μ M DFP (filled diamonds). Data were normalized to 100% in untreated cells and to 0% in FCCP (10 μ M)-treated cells. Graphs show means from experiments performed independently \pm standard errors ($n \ge 7$).




Figure 7. Effect of artemisinin and tetraoxane on the membrane potential in the presence of ROS scavenger. Time course of TMRE-dependent fluorescence of *P. falciparum*-infected erythrocytes after addition of (a) 100 nM artemisinin and (b) 100 nM tetraoxane. Cells are not treated (open circles) or subjected to ROS scavenger treatment with 100 μ M Tiron (filled circles). Data were normalized to 100% in untreated cells and to 0% in FCCP (10 μ M)-treated cells. Graphs show means from experiments performed independently \pm standard errors ($n \ge 7$).

data are consistent with the findings by Wang *et al.*,¹⁷ who reported depolarization of the membrane potential of isolated parasite mitochondria by artemisinin following 2 h of incubation. Crespo *et al.*⁴¹ reported mitochondrial dysfunction following exposure to artemisinin only after 8 h but not after 4 h, interpreting this as a downstream effect. We note, however, that the Crespo *et al.* study did not distinguish between $\Delta \Psi_p$ - or $\Delta \Psi_m$ -dependent rhodamine accumulation and that a washing step occurred in between

rhodamine staining and microscopy. As rhodamine is a cationic fluorophore, there is a balance between the concentration gradient of the probe and the total $\Delta \Psi$ according to the Nernst equation: $\Psi = RT/F \ln(P_{in}/P_{out})$, where R, T, F, D_{in} and D_{out} represent the universal gas constant, the absolute temperature, the Faraday constant and the intra- and extracellular probe concentrations, respectively. The washing step would therefore affect the distribution of the probe in a time-dependent manner and may account for the

discord between the data of Crespo et al. $^{\rm 41}$ and those presented here and by Wang et al. $^{\rm 17}$

Pretreatment of parasites with atovaquone in the perfusate further allowed the measurement of $\Delta\Psi_{
m p}$ alone. Exposure to endoperoxides resulted in the rapid depolarization of parasite $\Delta \Psi_{
m p}$ (Figure 5). The rapid onset of $\Delta \Psi_{
m p}$ depolarization exposed to pharmacologically relevant concentrations of endoperoxides indicates that this is a primary pharmacodynamic event leading to parasite death and is consistent with in vitro⁶³ and in vivo^{64,65} studies reporting the rapid killing rate of the endoperoxide class. The rapid onset of $\Delta \Psi_{\rm p}$ depolarization by endoperoxides is also consistent with studies demonstrating that short pulses of artemisinins (1-6 h) are sufficient for parasite kill, albeit with stage-dependent differences.^{66,67} It is also noteworthy that disruption of the parasite transmembrane pH gradient via inhibition of the V-type ATPase has been reported to drop the cytosolic pH by 0.4 pH units in <3 min and 0.5–0.6 units within 20 min,^{56,57} leading to the inhibition of parasite growth within 30 min to 4 h (depending on inhibitor concentration).

Deoxyartemisinin did not to have any depolarizing effect on either parasite $\Delta \Psi_{\rm p}$ or $\Delta \Psi_{\rm m}$ (Figure 2). This result is in line with previous studies^{17,68,69} and confirms the importance of the endoperoxide bond in mediating antimalarial activity.

Rapid depolarization of the parasite $\Delta \Psi_{\rm p}$ involves iron and ROS

The parasite's unique ability to digest haemoglobin is generally accepted to confer selective toxicity to endoperoxides (e.g. Klonis et al.²²) either directly, by activation of the endoperoxides by Fe^{2+5} and/or haem,⁷⁰ or indirectly through the ability of Fe^{3+} to oxidize cytosolic (reduced) cofactors.¹⁸ In this study, we used DFO and DFP, two known chelators of Fe^{3+} ,⁷¹ to determine the effect on endoperoxide-induced $\Delta \Psi_{
m p}$ depolarization. Addition of the chelators to the perfusate was clearly observed to confer a protective effect to the parasite upon exposure to the endoperoxides (Figure 6). These data can be interpreted to suggest that Fe^{3+} is involved in the depolarization of the parasite membrane. The ironmediated hypothesis of endoperoxide activation identifies a role for Fe²⁺. As the chelators have a much higher affinity for Fe³⁺ compared with Fe²⁺, such a mechanism would necessitate the additional presence of redox cycling activities, such as thiols $GSH \leftrightarrow GSSG$ (reduced and oxidized glutathione, respectively) and/or flavin enzymes. In previous experiments performed in situ using single-cell imaging, we observed that endoperoxideacridine adducts could be completely washed out in the presence of DFO, but remained irreversibly bound in the absence of DFO, suggesting that the drugs were being activated by iron to form stable covalent adducts.⁵² It is therefore possible that the protective effect of the iron chelators observed in our studies here is a result of a decrease in the bioactivation of the endoperoxides. An alternative or additional explanation is that the iron chelators conferred a protective effect by decreasing the generation of ROS through Fe²⁺-mediated oxidative stress such as the Fenton reaction, generating the highly membrane damaging hydroxyl radical ([•]OH). It is also noteworthy that DFO has been reported to be able to directly scavenge ROS.⁷² It should also be noted that in the experiments presented here, intracellular haem concentrations cannot be selectively and rapidly manipulated; therefore, the potential role of haem in the depolarization of $\Delta \Psi_{\rm p}$ by endoperoxides cannot be elucidated.

Although the exact protective mechanism for iron cannot be deduced from our data, a role for ROS is clearly demonstrated in experiments using Tiron, the superoxide anion (O_2^-) scavenger, showing a decreased rate of membrane depolarization following exposure to endoperoxides (Figure 7). The indiscriminate nature of the depolarization of both $\Delta\Psi_p$ or $\Delta\Psi_m$ is suggestive of a mechanism involving the general lipid peroxidation of the parasite membranes; however, in addition to this, a specific inhibition of key enzymes such as the V-type ATPase by ROS cannot be ruled out.⁷³

Conclusions

In summary, this study reports that rapid loss of $\Delta \Psi_p$ following exposure to endoperoxides is a primary physiological event leading to parasite death. A loss of $\Delta \Psi_m$ is also reported, but the lack of direct inhibition of ETC H⁺-pumping complexes by endoperoxides and the indiscriminate nature of membrane depolarization is consistent with a non-ETC mode of action, as reported recently in mammalian cells.⁴² The rapid depolarization of $\Delta \Psi_p$ by endoperoxides involves ROS and iron, but it is not discernible from this study whether iron plays a role in endoperoxide bioactivation and/or ironmediated oxidative stress.

Acknowledgements

We thank the staff and patients of Ward 7Y and the Gastroenterology Unit, Royal Liverpool Hospital, for their generous donation of blood.

Funding

This work was supported by grants from the MRC, Leverhulme Trust, the Wellcome Trust and the European Union Framework 7 Marie Curie Initial Training Network 215281 (InterMalTraining).

Transparency declarations

None to declare.

Supplementary data

Figure S1 is available as Supplementary data at JAC Online (http://jac. oxfordjournals.org/).

References

1 Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. *Science* 1985; **228**: 1049–55.

2 Charman SA, Arbe-Barnes S, Bathurst IC *et al.* Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. *Proc Natl Acad Sci USA* 2011; **108**: 4400–5.

3 O'Neill PM, Amewu RK, Nixon GL *et al.* Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. *Angew Chem Int Ed Engl* 2010; **49**: 5693–7.

4 O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin—the debate continues. *Molecules* 2010; **15**: 1705–21.

5 Meshnick SR, Yang YZ, Lima V *et al.* Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). *Antimicrob Agents Chemother* 1993; **37**: 1108–14.

6 Meshnick SR, Thomas A, Ranz A *et al*. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. *Mol Biochem Parasitol* 1991; **49**: 181–9.

7 Posner GH, Oh CH, Wang D *et al*. Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of a carbon-centered radical for antimalarial activity. *J Med Chem* 1994; **37**: 1256–8.

8 Posner GH, Wang D, Cumming JN *et al*. Further evidence supporting the importance of and the restrictions on a carbon-centered radical for high antimalarial activity of 1,2,4-trioxanes like artemisinin. *J Med Chem* 1995; **38**: 2273–5.

9 Butler AR, Gilbert BC, Hulme P *et al.* EPR evidence for the involvement of free radicals in the iron-catalysed decomposition of qinghaosu (artemisinin) and some derivatives; antimalarial action of some polycyclic endoperoxides. *Free Radic Res* 1998; **28**: 471–6.

10 O'Neill PM, Bishop LP, Searle NL *et al.* Biomimetic Fe(II)-mediated degradation of arteflene (Ro-42-1611). The first EPR spin-trapping evidence for the previously postulated secondary carbon-centered cyclohexyl radical. *J Org Chem* 2000; **65**: 1578–82.

11 Wu W-M, Wu Y, Wu Y-L *et al.* Unified mechanistic framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the previously postulated secondary C-4 radical. *J Am Chem Soc* 1998; **120**: 3316–25.

12 Robert A, Benoit-Vical F, Claparols C *et al*. The antimalarial drug artemisinin alkylates heme in infected mice. *Proc Natl Acad Sci USA* 2005; **102**: 13676–80.

13 Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. *Acc Chem Res* 2002; **35**: 255–9.

14 Haynes RK, Chan WC, Lung CM *et al.* The Fe²⁺-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. *ChemMedChem* 2007; **2**: 1480–97.

15 Haynes RK, Pai HH-O, Voerste A. Ring opening of artemisinin (qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides—a chemical model for antimalarial mode of action. *Tetrahedron Lett* 1999; **40**: 4715–8.

16 Li W, Mo W, Shen D et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. *PLoS Genetics* 2005; **1**: e36.

17 Wang J, Huang L, Li J *et al*. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. *PLoS One* 2010; **5**: e9582.

18 Haynes RK, Cheu KW, Chan HW *et al.* Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model—a unifying proposal for drug action. *Chem Med Chem* 2012; **7**: 2204–26.

19 Olliaro P. Mode of action and mechanisms of resistance for antimalarial drugs. *Pharmacol Ther* 2001; **89**: 207–19.

20 Golenser J, Waknine JH, Krugliak M *et al.* Current perspectives on the mechanism of action of artemisinins. *Int J Parasitol* 2006; **36**: 1427-41.

21 Maeno Y, Toyoshima T, Fujioka H *et al*. Morphologic effects of artemisinin in *Plasmodium falciparum*. *Am J Trop Med Hyg* 1993; **49**: 485–91.

22 Klonis N, Crespo-Ortiz MP, Bottova I *et al*. Artemisinin activity against *Plasmodium falciparum* requires hemoglobin uptake and digestion. *Proc Natl Acad Sci USA* 2011; **108**: 11405–10.

23 Berman PA, Adams PA. Artemisinin enhances heme-catalysed oxidation of lipid membranes. *Free Rad Biol Med* 1997; **22**: 1283–8.

24 Pandey AV, Tekwani BL, Singh RL *et al*. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. *J Biol Chem* 1999; **274**: 19383–8.

25 Kannan R, Sahal D, Chauhan VS. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization. *Chem Biol* 2002; **9**: 321–32.

26 Zhang S, Gerhard GS. Heme activates artemisinin more efficiently than hemin, inorganic iron, or hemoglobin. *Bioorg Med Chem* 2008; **16**: 7853–61.

27 Hartwig CL, Rosenthal AS, D'Angelo J *et al*. Accumulation of artemisinin trioxane derivatives within neutral lipids of *Plasmodium falciparum* malaria parasites is endoperoxide-dependent. *Biochem Pharmacol* 2009; **77**: 322 – 36.

28 Pisciotta JM, Coppens I, Tripathi AK *et al*. The role of neutral lipid nanospheres in *Plasmodium falciparum* haem crystallization. *Biochem J* 2007; **402**: 197–204.

29 Ellis DS, Li ZL, Gu HM *et al.* The chemotherapy of rodent malaria, XXXIX. Ultrastructural changes following treatment with artemisinine of *Plasmodium berghei* infection in mice, with observations of the localization of [3H]-dihydroartemisinine in *P. falciparum* in vitro. *Ann Trop Med Parasitol* 1985; **79**: 367–74.

30 Eckstein-Ludwig U, Webb RJ, Van Goethem ID *et al*. Artemisinins target the SERCA of *Plasmodium falciparum*. *Nature* 2003; **424**: 957–61.

31 Haynes RK, Ho WY, Chan HW *et al.* Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. *Angew Chem Int Ed Engl* 2004; **43**: 1381–5.

32 Haynes RK, Monti D, Taramelli D *et al*. Artemisinin antimalarials do not inhibit hemozoin formation. *Antimicrob Agents Chemother* 2003; **47**: 1175.

33 Pradines B, Rolain JM, Ramiandrasoa F et al. Iron chelators as antimalarial agents: *in vitro* activity of dicatecholate against *Plasmodium falciparum*. J Antimicrob Chemother 2002; **50**: 177–87.

34 Bhisutthibhan J, Pan XQ, Hossler PA *et al*. The *Plasmodium falciparum* translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. *J Biol Chem* 1998; **273**: 16192–8.

35 Jiang JB, Jacobs G, Liang DS *et al*. Qinghaosu-induced changes in the morphology of *Plasmodium inui*. *Am J Trop Med Hyg* 1985; **34**: 424–8.

36 Kawai S, Kano S, Suzuki M. Morphologic effects of artemether on *Plasmodium falciparum* in *Aotus trivirgatus*. *Am J Trop Med Hyg* 1993; **49**: 812–8.

37 Zhao Y, Hanton WK, Lee KH. Antimalarial agents, 2. Artesunate, an inhibitor of cytochrome oxidase activity in *Plasmodium berghei*. *J Nat Prod* 1986; **49**: 139–42.

38 Krungkrai J, Burat D, Kudan S *et al*. Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, *Plasmodium falciparum. Southeast Asian J Trop Med Public Health* 1999; **30**: 636–42.

39 Fisher N, Bray PG, Ward SA *et al.* The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. *Trends Parasitol* 2007; **23**: 305–10.

40 Fisher N, Warman A, Ward SA *et al*. Type II NADH:quinone oxidoreductases of *Plasmodium falciparum* and *Mycobacterium tuberculosis*: kinetic and high-throughput assays. *Methods Enzymol* 2009; **456**: 303–20.

41 del Pilar Crespo M, Avery TD, Hanssen E *et al*. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. *Antimicrob Agents Chemother* 2008; **52**: 98–109.

42 Mercer AE, Copple IM, Maggs JL *et al.* The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. *J Biol Chem* 2011; **286**: 987–96.

43 Biagini GA, Viriyavejakul P, O'Neill PM *et al.* Functional characterization and target validation of alternative complex I of *Plasmodium falciparum* mitochondria. *Antimicrob Agents Chemother* 2006; **50**: 1841–51.

44 Biagini GA, Fisher N, Berry N *et al.* Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. *Mol Pharmacol* 2008; **73**: 1347–55.

45 Fisher N, Majid RA, Antoine T *et al*. Cytochrome *b* mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc_1 catalytic turnover and protein expression. *J Biol Chem* 2012; **287**: 9731–41.

46 Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science* 1976; **193**: 673–5.

47 Lambros C, Vanderberg JP. Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J Parasitol* 1979; **65**: 418–20.

48 Smilkstein M, Sriwilaijaroen N, Kelly JX *et al.* Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrob Agents Chemother* 2004; **48**: 1803–6.

49 Fisher N, Castleden CK, Bourges I *et al.* Human disease-related mutations in cytochrome b studied in yeast. *J Biol Chem* 2004; **279**: 12951–8.

50 Lenaz G, Fato R, Baracca A *et al*. Mitochondrial quinone reductases: complex I. *Methods Enzymol* 2004; **382**: 3–20.

51 Allen RJ, Kirk K. The membrane potential of the intraerythrocytic malaria parasite *Plasmodium falciparum*. *J Biol Chem* 2004; **279**: 11264–72.

52 Stocks PA, Bray PG, Barton VE *et al.* Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. *Angew Chem Int Ed Engl* 2007; **46**: 6278–83.

53 Lloyd D, Hayes AJ. Vigor, vitality and viability of microorganisms. *FEMS Microbiol Lett* 1995; **133**: 1–7.

54 Izumo A, Tanabe K, Kato M. The plasma membrane and mitochondrial membrane potentials of *Plasmodium yoelii*. *Comp Biochem Physiol B* 1988; **91**: 735–9.

55 Hayashi M, Yamada H, Mitamura T*et al*. Vacuolar H⁺-ATPase localized in plasma membranes of malaria parasite cells, *Plasmodium falciparum*, is involved in regional acidification of parasitized erythrocytes. *J Biol Chem* 2000; **275**: 34353–8.

56 Saliba KJ, Kirk K. pH regulation in the intracellular malaria parasite, *Plasmodium falciparum*. H⁺ extrusion via a V-type H⁺-ATPase. *J Biol Chem* 1999; **274**: 33213–9.

57 van Schalkwyk DA, Chan XW, Misiano P *et al*. Inhibition of *Plasmodium falciparum* pH regulation by small molecule indole derivatives results in rapid parasite death. *Biochem Pharmacol* 2010; **79**: 1291–9.

58 Lehane AM, Saliba KJ, Allen RJ *et al.* Choline uptake into the malaria parasite is energized by the membrane potential. *Biochem Biophys Res Commun* 2004; **320**: 311–7.

59 Biagini GA, Pasini EM, Hughes R *et al.* Characterization of the choline carrier of *Plasmodium falciparum*: a route for the selective delivery of novel antimalarial drugs. *Blood* 2004; **104**: 3372–7.

60 Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. *J Biol Chem* 1997; **272**: 3961–6.

61 Hammond DJ, Burchell JR, Pudney M. Inhibition of pyrimidine biosynthesis de novo in *Plasmodium falciparum* by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. *Mol Biochem Parasitol* 1985; **14**: 97–109.

62 Painter HJ, Morrisey JM, Mather MW *et al*. Specific role of mitochondrial electron transport in blood-stage *Plasmodium falciparum*. *Nature* 2007; **446**: 88–91.

63 Sanz LM, Crespo B, De-Cozar C *et al. P. falciparum* in vitro killing rates allow to discriminate between different antimalarial mode-of-action. *PLoS One* 2012; **7**: e30949.

64 White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents Chemother* 1997; **41**: 1413–22.

65 Pukrittayakamee S, Chantra A, Simpson JA *et al*. Therapeutic responses to different antimalarial drugs in vivax malaria. *Antimicrob Agents Chemother* 2000; **44**: 1680–5.

66 Klonis N, Xie SC, McCaw JM *et al.* Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. *Proc Natl Acad Sci USA* 2013; **110**: 5157–62.

67 Makanga M, Bray PG, Horrocks P *et al*. Towards a proteomic definition of CoArtem action in *Plasmodium falciparum* malaria. *Proteomics* 2005; **5**: 1849–58.

68 Brossi A, Venugopalan B, Dominguez Gerpe L *et al*. Arteether, a new antimalarial drug: synthesis and antimalarial properties. *J Med Chem* 1988; **31**: 645–50.

69 Kaiser M, Wittlin S, Nehrbass-Stuedli A *et al.* Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). *Antimicrob Agents Chemother* 2007; **51**: 2991–3.

70 Hong YL, Yang YZ, Meshnick SR. The interaction of artemisinin with malarial hemozoin. *Mol Biochem Parasitol* 1994; **63**: 121–8.

71 Schwarzenbach G, Anderegg G. [Metal complexes with biguanide]. *Pharmaceutica Acta Helvetiae* 1963; **38**: 547–52.

72 Morel I, Cillard J, Lescoat G *et al*. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. *Free Radic Biol Med* 1992; **13**: 499–508.

73 van Schalkwyk DA, Saliba KJ, Biagini GA *et al.* Loss of pH control in *Plasmodium falciparum* parasites subjected to oxidative stress. *PLoS One* 2013; **8**: e58933.